BGLA.F BIOGAIA AB B O.N.
- Market cap
- EUR 1.14B
- P/E
- 31.2x
- P/B
- 10.30x
- ROE
- 32.0%
- Dividend yield
- 1.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BGLA.F undervalued?
Graham numberThe Graham number of BIOGAIA AB B O.N. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOGAIA AB B O.N. fundamental analysis
No fundamental analysis for BIOGAIA AB B O.N. yet.
BIOGAIA AB B O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOGAIA AB B O.N.
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. I…
Full company profileBIOGAIA AB B O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOGAIA AB B O.N. annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.10B | 1.30B | 1.42B | 1.54B | 1.62B |
| Gross Profit | 802M | 950M | 1.03B | 1.13B | 1.17B |
| Operating Income | 335M | 441M | 409M | 452M | 488M |
| EBITDA | 477M | 495M | 475M | 452M | 521M |
| Net Income | 374M | 365M | 351M | 333M | 390M |
| EPS | 3.70 | 3.62 | 3.47 | 3.29 | 3.86 |
| Balance Sheet | |||||
| Total Assets | 2.21B | 2.33B | 2.03B | 1.60B | 1.45B |
| Total Liabilities | 242M | 303M | 310M | 284M | 230M |
| Shareholders' Equity | 1.97B | 2.03B | 1.72B | 1.31B | 1.22B |
| Cash & Short-term Investments | 1.49B | 1.54B | 1.22B | 801M | 518M |
| Cash Flow | |||||
| Operating Cash Flow | 319M | 426M | 373M | 307M | 268M |
| Capital Expenditure | 18.1M | 48.7M | 14.2M | 3.60M | 33.8M |
| Free Cash Flow | 301M | 377M | 359M | 303M | 234M |
| Ratios | |||||
| ROE | 19.0% | 18.0% | 20.4% | 25.3% | 32.0% |
| ROA | 16.9% | 15.7% | 17.3% | 20.8% | 26.9% |
| Net Profit Margin | 33.9% | 28.2% | 24.7% | 21.6% | 24.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOGAIA AB B O.N. dividends
- Dividend yield
- 1.33%
- Forward dividend
- 0.15 EUR
- Payout ratio
- 209.8%
- Ex-dividend date
- May 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 698M | 6.90 | 209.8% |
| 2024 | SEK 697M | 6.89 | 198.3% |
| 2023 | SEK 293M | 2.90 | 80.2% |
| 2022 | SEK 301M | 2.98 | 80.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on May 18, 2022.
Who owns BIOGAIA AB B O.N.
- Insiders 17.00%
- Institutions 51.70%
- Public & others 31.30%
- Shares outstanding 98.5M
- Free float 83.9M
BIOGAIA AB B O.N. company profile
- Company name
- BIOGAIA AB B O.N.
- Ticker
- BGLA.F
- ISIN
- SE0017769995
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 251
- Fiscal year end
- December
- Address
- Kungsbroplan 3, Stockholm, Sweden, 112 27
- Phone
- 46 8 55 52 93 00
- Website
- biogaiagroup.com
About BIOGAIA AB B O.N.
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
BIOGAIA AB B O.N. management
10- Ms. Theresa P. AgnewCEO & President · born 1966
- Mr. Alexander Kotsinas M.Sc. (Eng.).Executive VP & CFO · born 1967
- Ludvig MilessonChief Operating Officer · born 1977
- Mr. Gianfranco GromponeChief Scentific Officer · born 1975
- Ms. Caroline MoforsExecutive VP & Chief Legal Officer · born 1972
- Ms. Linda HagglundChief Marketing Officer · born 1973
- Ms. Angelika KjelldorffChief Human Resources Officer · born 1969
- Minna TähtinenManaging Director Finland
- Jennifer CherryManaging Director USA
- Mr. Darryl MalletteManaging Director Canada